2024
Sex differences in the acute effects of oral THC: a randomized, placebo-controlled, crossover human laboratory study
Mohammad Aghaei A, Urban Spillane L, Pittman B, Flynn L, De Aquino J, Bassir Nia A, Ranganathan M. Sex differences in the acute effects of oral THC: a randomized, placebo-controlled, crossover human laboratory study. Psychopharmacology 2024, 241: 2145-2155. PMID: 38832949, DOI: 10.1007/s00213-024-06625-6.Peer-Reviewed Original ResearchRey Auditory Verbal Learning TestCannabis use disorderHuman laboratory studiesOral tetrahydrocannabinolPsychoactive effectsSex differencesAuditory Verbal Learning TestDissociative Symptoms ScalePsychotomimetic States InventoryExposure to cannabisVerbal Learning TestPlacebo-controlledIncreased cannabis useInvestigate sex differencesClinician-AdministeredVerbal learningPsychotomimetic effectsCannabinoid effectsLearning TestCannabis useTetrahydrocannabinol dosesEffects of sexUse disorderDose-related effectsIndividual vulnerabilityPsychotherapeutic Interventions in Clinical Trials of Psychedelics for the Treatment of Alcohol Use Disorder
Mohammad Aghaei A, Weleff J, Martins B, Ing K, Fontenele R, Barnett B, Anand A, Bassir Nia A. Psychotherapeutic Interventions in Clinical Trials of Psychedelics for the Treatment of Alcohol Use Disorder. Current Addiction Reports 2024, 11: 685-712. DOI: 10.1007/s40429-024-00574-y.Peer-Reviewed Original ResearchTreatment of AUDUse disorderTreatment of alcohol use disordersModalities of psychotherapyAlcohol use disorderPsychedelic treatmentPsychotherapeutic interventionsTreat AUDPsychedelic compoundsPsychedelic trialsPsychotherapySmall numbers of participantsPsychedelicsMagnitude of improvementMethodological shortcomingsAUDNumbers of participantsClinical trialsDisordersReviewed trialsShort follow-up periodFollow-up periodTherapy methodsEmpirical evidenceNo significant difference
2023
Dysregulation of the endogenous cannabinoid system following opioid exposure
Mohammad Aghaei A, Saali A, Canas M, Weleff J, D'Souza D, Angarita G, Bassir Nia A. Dysregulation of the endogenous cannabinoid system following opioid exposure. Psychiatry Research 2023, 330: 115586. PMID: 37931479, PMCID: PMC10842415, DOI: 10.1016/j.psychres.2023.115586.Peer-Reviewed Original ResearchConceptsEndocannabinoid systemECS componentsBrain regionsNovel neurobiological targetsTreatment of OUDEndogenous opioid systemOpioid-related deathsEndogenous cannabinoid systemSpecific brain regionsECS dysregulationOpioid exposureOUD treatmentOpioid systemCannabinoid systemNeurobiological targetsNew medicationsPreclinical literatureCannabinoid receptorsEndogenous ligandTherapeutic potentialStudy typePresent potential targetsExposure protocolOpioidsPreclinical researchRegular cannabis use is associated with history of childhood and lifetime trauma in a non-clinical community sample
Bassir Nia A, Weleff J, Fogelman N, Nourbakhsh S, Sinha R. Regular cannabis use is associated with history of childhood and lifetime trauma in a non-clinical community sample. Journal Of Psychiatric Research 2023, 159: 159-164. PMID: 36736285, PMCID: PMC10024801, DOI: 10.1016/j.jpsychires.2023.01.036.Peer-Reviewed Original ResearchConceptsMajor life eventsChildhood traumaLife eventsChildhood Trauma QuestionnaireLifetime traumaCannabis useNon-clinical community sampleChronic stressNeurobiology of stressRegular cannabis useGender differencesRegular useSelf-report questionnairesRecent life eventsPotential gender differencesCross-sectional studyUrine drug testingLife traumaLogistic regression analysisAdversity indexCommunity sampleCannabis usersTrauma QuestionnaireHigh rateSubstance use
2022
Sex differences in the acute effects of intravenous (IV) delta-9 tetrahydrocannabinol (THC)
Bassir Nia A, Orejarena MJ, Flynn L, Luddy C, D’Souza D, Skosnik PD, Pittman B, Ranganathan M. Sex differences in the acute effects of intravenous (IV) delta-9 tetrahydrocannabinol (THC). Psychopharmacology 2022, 239: 1621-1628. PMID: 35438304, PMCID: PMC11215802, DOI: 10.1007/s00213-022-06135-3.Peer-Reviewed Original ResearchConceptsRey Auditory Verbal Learning TaskPsychotomimetic States InventoryCognitive effectsAuditory Verbal Learning TaskSubjective effectsDelta-9-TetrahydrocannabinolSex differencesVerbal learning taskDissociative Symptoms ScaleFemale participantsMain psychoactive constituentSignificant main effectPerceptual alterationsLearning taskStates InventoryPsychoactive constituentSignificant sex differencesMain effectMale participantsVisual analog scaleSymptom ScaleTest dayEffects of cannabinoidsParticipantsPsychotomimetic effectsDiagnostic and Statistical Manual of Mental Disorders, Text Revision Dsm-5-tr 5th Edition
Cross-Cutting Gender Review Group, Diagnostic and Statistical Manual of Mental Disorders, Text Revision Dsm-5-tr 5th EditionBooks
2021
Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia
Abi-Dargham A, Javitch JA, Slifstein M, Anticevic A, Calkins ME, Cho YT, Fonteneau C, Gil R, Girgis R, Gur RE, Gur RC, Grinband J, Kantrowitz J, Kohler C, Krystal J, Murray J, Ranganathan M, Santamauro N, Van Snellenberg J, Tamayo Z, Wolf D, D’Souza D, Srihari V, Gueorguieva R, Patel P, Forselius-Bielen K, Lu J, Butler A, Fram G, Afriyie-Agyemang Y, Selloni A, Cadavid L, Gomez-Luna S, Gupta A, Radhakrishnan R, Rashid A, Aker R, Abrahim P, Nia A, Surti T, Kegeles L, Carlson M, Goldberg T, Gangwisch J, Benedict E, Govil P, Brazis S, Mayer M, de la Garrigue N, Fallon N, Baumvoll T, Abeykoon S, Perlman G, Bobchin K, Elliott M, Schmidt L, Rush S, Port A, Heffernan Z, Laney N, Kantor J, Hohing T, Gray D, Lieberman J. Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia. Schizophrenia Bulletin 2021, 48: 199-210. PMID: 34423843, PMCID: PMC8781338, DOI: 10.1093/schbul/sbab095.Peer-Reviewed Original ResearchConceptsCortical dopamine neurotransmissionPositive allosteric modulationImportant therapeutic targetPF-06412562Dopaminergic receptorsD1R stimulationDA levelsTolerable dosesLevel of stimulationDopamine neurotransmissionReceptor stimulationTherapeutic targetPartial agonistCognitive deficitsBiased agonismFull agonismTarget engagementAllosteric modulationNew drugsStimulationPoor bioavailabilitySchizophreniaOptimal stimulationDrugsExpression levels
2020
Cannabinoid use in psychotic patients impacts inflammatory levels and their association with psychosis severity
Gibson CL, Bassir Nia A, Spriggs SA, DeFrancisco D, Swift A, Perkel C, Zhong X, Mazumdar M, Fernandez N, Patel M, Kim-Schulze S, Hurd YL. Cannabinoid use in psychotic patients impacts inflammatory levels and their association with psychosis severity. Psychiatry Research 2020, 293: 113380. PMID: 32818918, PMCID: PMC8292796, DOI: 10.1016/j.psychres.2020.113380.Peer-Reviewed Original ResearchConceptsInterleukin-6Psychosis severityCannabinoid useCannabis useIL-6 levelsCommon underlying pathologyPANSS total scoreChronic psychotic disordersRisk of psychosisPsychiatric emergency roomNegative Syndrome ScalePsychotic symptom severityInflammatory alterationsInflammatory markersInflammatory disturbancesAcute psychosisInflammatory abnormalitiesNata medicationUnderlying pathologyEmergency roomInflammatory levelsPANSS scoresPsychiatric unitUnadjusted modelsPsychotic disordersMultimodal Computational Modeling of Visual Object Recognition Deficits but Intact Repetition Priming in Schizophrenia.
Sehatpour P, Bassir Nia A, Adair D, Wang Z, DeBaun HM, Silipo G, Martinez A, Javitt DC. Multimodal Computational Modeling of Visual Object Recognition Deficits but Intact Repetition Priming in Schizophrenia. Frontiers In Psychiatry 2020, 11: 547189. PMID: 33329086, PMCID: PMC7719812, DOI: 10.3389/fpsyt.2020.547189.Peer-Reviewed Original Research
2019
The Relevance of Sex in the Association of Synthetic Cannabinoid Use With Psychosis and Agitation in an Inpatient Population.
Bassir Nia A, Mann CL, Spriggs S, DeFrancisco DR, Carbonaro S, Parvez L, Galynker II, Perkel CA, Hurd YL. The Relevance of Sex in the Association of Synthetic Cannabinoid Use With Psychosis and Agitation in an Inpatient Population. The Journal Of Clinical Psychiatry 2019, 80 PMID: 31265768, PMCID: PMC8445109, DOI: 10.4088/jcp.18m12539.Peer-Reviewed Original ResearchConceptsToxicology screenRelevance of sexSynthetic cannabinoid useSC usePositive urine toxicology screenCannabinoid useUrine toxicology screenRetrospective chart reviewPositive toxicology screenEffects of cannabinoidsSC usersRates of psychosisChart reviewPharmacologic treatmentClinical symptomsInpatient populationInpatient settingPsychotic presentationsUse of substancesStudy groupHigh riskPsychiatric unitCurrent evidenceControl groupPsychosisCannabidiol as an Adjunctive Treatment for Schizophrenia
Psychiatric Times 4 (36)Commentaries, Editorials and Letters
2018
Cannabis Use: Neurobiological, Behavioral, and Sex/Gender Considerations
Bassir Nia A, Mann C, Kaur H, Ranganathan M. Cannabis Use: Neurobiological, Behavioral, and Sex/Gender Considerations. Current Behavioral Neuroscience Reports 2018, 5: 271-280. PMID: 31548918, PMCID: PMC6756752, DOI: 10.1007/s40473-018-0167-4.Peer-Reviewed Original ResearchEffects of cannabinoidsGender-related differencesMood/psychotic disordersPurpose of ReviewToSex/gender considerationsRate of useRisk of addictionAdverse outcomesClinical dataPsychotic disordersCognitive deficitsConstituent cannabinoidsGreater riskSubstance useCannabinoidsWomenHuman dataCurrent literatureFuture studiesSexRiskCurrent Knowledge on Gene-Environment Interactions in Personality Disorders: an Update
Bulbena-Cabre A, Bassir Nia A, Perez-Rodriguez MM. Current Knowledge on Gene-Environment Interactions in Personality Disorders: an Update. Current Psychiatry Reports 2018, 20: 74. PMID: 30094700, DOI: 10.1007/s11920-018-0934-7.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBorderline personality disorderGene-environment interactionsPersonality disorderAvoidant personality disorderNew therapeutic dimensionPurpose of ReviewWeEpigenetic changesPharmacological treatmentTherapeutic approachesMost personality disordersChildhood sexual abuseDisordersRecent FindingsResearchSusceptibility genesCurrent knowledgeFuture studiesTherapeutic dimensionPast, present, and future of genetic research in borderline personality disorder.
Bassir Nia A, Eveleth MC, Gabbay JM, Hassan YJ, Zhang B, Perez-Rodriguez MM. Past, present, and future of genetic research in borderline personality disorder. Current Opinion In Psychology 2018, 21: 60-68. PMID: 29032046, PMCID: PMC5847441, DOI: 10.1016/j.copsyc.2017.09.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCannabidiol, an Adjunct Player in the Antipsychosis Arsenal
Bassir Nia A, Hurd YL. Cannabidiol, an Adjunct Player in the Antipsychosis Arsenal. American Journal Of Psychiatry 2018, 175: 197-198. PMID: 29490489, DOI: 10.1176/appi.ajp.2017.17121295.Commentaries, Editorials and LettersCannabis Use: Neurobiological, Behavioral, and Sex/Gender Considerations
Current Behavioral Neuroscience ReportsPeer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2017
Opioid addiction and borderline personality disorder
Bassir Nia A. Opioid addiction and borderline personality disorder. American Journal On Addictions 2017, 27: 54-55. PMID: 29283477, DOI: 10.1111/ajad.12664.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2016
Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis.
Bassir Nia A, Medrano B, Perkel C, Galynker I, Hurd YL. Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis. Journal Of Psychopharmacology (Oxford, England) 2016, 30: 1321-1330. PMID: 27462088, DOI: 10.1177/0269881116658990.Peer-Reviewed Original ResearchSynthetic Cannabinoids and the Pressing Need to Detect the Undetectable.
AAAP Newsletter 32 (3):12Commentaries, Editorials and Letters
2015
Relationship between personality traits and perceived internalized stigma in bipolar patients and their treatment partners.
Bassirnia A, Briggs J, Kopeykina I, Mednick A, Yaseen Z, Galynker I. Relationship between personality traits and perceived internalized stigma in bipolar patients and their treatment partners. Psychiatry Research 2015, 230: 436-40. PMID: 26421901, DOI: 10.1016/j.psychres.2015.09.033.Peer-Reviewed Original Research